{"id":"https://openalex.org/W3097451869","doi":"https://doi.org/10.1182/blood-2020-137440","title":"Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma","display_name":"Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma","publication_year":2020,"publication_date":"2020-11-04","ids":{"openalex":"https://openalex.org/W3097451869","doi":"https://doi.org/10.1182/blood-2020-137440","mag":"3097451869"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-137440","doi":"https://doi.org/10.1182/blood-2020-137440","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-137440","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5083223035","display_name":"Preetesh Jain","orcid":"https://orcid.org/0000-0003-2735-168X","observed_orcids":["https://orcid.org/0000-0003-2735-168X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Preetesh Jain","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100607388","display_name":"Shaojun Zhang","orcid":"https://orcid.org/0000-0001-5760-5797","observed_orcids":["https://orcid.org/0000-0001-5760-5797"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shaojun Zhang","raw_affiliation_strings":["Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059373442","display_name":"Rashmi Kanagal\u2010Shamanna","orcid":"https://orcid.org/0000-0001-7829-5249","observed_orcids":["https://orcid.org/0000-0001-7829-5249"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rashmi Kanagal-Shamanna","raw_affiliation_strings":["Department of Hematopathology, Division of Pathology/Lab Medicine, University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematopathology, Division of Pathology/Lab Medicine, University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024681090","display_name":"Lucy Jayne Navsaria","orcid":"https://orcid.org/0000-0003-0360-5374","observed_orcids":["https://orcid.org/0000-0003-0360-5374"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lucy Navsaria","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053926894","display_name":"Chi Young Ok","orcid":"https://orcid.org/0000-0002-6822-7880","observed_orcids":["https://orcid.org/0000-0002-6822-7880"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chi Young Ok","raw_affiliation_strings":["Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055404021","display_name":"Guilin Tang","orcid":"https://orcid.org/0000-0002-9482-4806","observed_orcids":["https://orcid.org/0000-0002-9482-4806"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guilin Tang","raw_affiliation_strings":["Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006583715","display_name":"C. Cameron Yin","orcid":"https://orcid.org/0000-0001-6630-4128","observed_orcids":["https://orcid.org/0000-0001-6630-4128"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Cameron Yin","raw_affiliation_strings":["Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109602194","display_name":"Maria Badillo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maria Badillo","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008617175","display_name":"Wendy Chen","orcid":"https://orcid.org/0000-0003-2771-5324","observed_orcids":["https://orcid.org/0000-0003-2771-5324"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wendy Chen","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110626779","display_name":"Onyeka Oriabure","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Onyeka Oriabure","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024844183","display_name":"Hun Ju Lee","orcid":"https://orcid.org/0000-0001-7219-5562","observed_orcids":["https://orcid.org/0000-0001-7219-5562"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hun Ju Lee","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021496101","display_name":"Jason R. Westin","orcid":"https://orcid.org/0000-0002-1824-2337","observed_orcids":["https://orcid.org/0000-0002-1824-2337"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Westin","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037878906","display_name":"Loretta J. Nastoupil","orcid":"https://orcid.org/0000-0001-6071-8610","observed_orcids":["https://orcid.org/0000-0001-6071-8610"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Loretta J. Nastoupil","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059853176","display_name":"Omar Moghrabi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Omar Moghrabi","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101503606","display_name":"Yuxuan Che","orcid":"https://orcid.org/0000-0002-0714-6411","observed_orcids":["https://orcid.org/0000-0002-0714-6411"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yuxuan Che","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070455368","display_name":"Felipe Samaniego","orcid":"https://orcid.org/0000-0001-6931-4583","observed_orcids":["https://orcid.org/0000-0001-6931-4583"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Felipe Samaniego","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039574726","display_name":"Sairah Ahmed","orcid":"https://orcid.org/0000-0001-7302-8299","observed_orcids":["https://orcid.org/0000-0001-7302-8299"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sairah Ahmed","raw_affiliation_strings":["Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111552833","display_name":"Ranjit K. Nair","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ranjit Nair","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101659644","display_name":"Shaoying Li","orcid":"https://orcid.org/0000-0002-6857-0523","observed_orcids":["https://orcid.org/0000-0002-6857-0523","https://orcid.org/0009-0006-4295-0567"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shaoying Li","raw_affiliation_strings":["Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006947975","display_name":"Francisco Vega","orcid":"https://orcid.org/0000-0001-5956-452X","observed_orcids":["https://orcid.org/0000-0001-5956-452X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Francisco Vega","raw_affiliation_strings":["Division of Hematopathology, Department of Pathology and Laboratory Medicine, MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematopathology, Department of Pathology and Laboratory Medicine, MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082892912","display_name":"Christopher R. Flowers","orcid":"https://orcid.org/0000-0002-9524-3990","observed_orcids":["https://orcid.org/0000-0002-9524-3990"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher Flowers","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051182441","display_name":"Linghua Wang","orcid":"https://orcid.org/0000-0001-9380-0266","observed_orcids":["https://orcid.org/0000-0001-9380-0266","https://orcid.org/0000-0003-3117-1390"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Linghua Wang","raw_affiliation_strings":["Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100438316","display_name":"Michael L. Wang","orcid":"https://orcid.org/0000-0001-9748-5486","observed_orcids":["https://orcid.org/0000-0001-9748-5486"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Wang","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.322,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.58099772,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"136","issue":"Supplement 1","first_page":"9","last_page":"10"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.008999999612569809,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12212","display_name":"CNS Lymphoma Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acalabrutinib","display_name":"acalabrutinib","score":0.9909999966621399},{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.8759999871253967},{"id":"https://openalex.org/keywords/relapsed-lymphoma","display_name":"relapsed lymphoma","score":0.824999988079071},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.7559999823570251},{"id":"https://openalex.org/keywords/medication-discontinuation","display_name":"drug discontinuation","score":0.7049999833106995},{"id":"https://openalex.org/keywords/treatment-intolerance","display_name":"treatment intolerance","score":0.5490000247955322},{"id":"https://openalex.org/keywords/disease-progression","display_name":"disease progression","score":0.765999972820282},{"id":"https://openalex.org/keywords/btk-mutations","display_name":"BTK mutations","score":0.5789999961853027},{"id":"https://openalex.org/keywords/btk-inhibitor-resistance","display_name":"BTK inhibitor resistance","score":0.35899999737739563},{"id":"https://openalex.org/keywords/cardiotoxicity","display_name":"cardiotoxicity","score":0.367000013589859},{"id":"https://openalex.org/keywords/atrial-fibrillation","display_name":"atrial fibrillation","score":0.7580000162124634},{"id":"https://openalex.org/keywords/mutational-landscape","display_name":"mutational landscape","score":0.5270000100135803},{"id":"https://openalex.org/keywords/treatment-outcomes","display_name":"treatment outcomes","score":0.32199999690055847},{"id":"https://openalex.org/keywords/salvage-therapy","display_name":"salvage therapy","score":0.40299999713897705},{"id":"https://openalex.org/keywords/relapse-after-relapse","display_name":"relapse after relapse","score":0.3529999852180481}],"concepts":[{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.8803566694259644},{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.7944470643997192},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6820991039276123},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.6440137028694153},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6250783205032349},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4538695514202118},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.41561323404312134},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.41187116503715515},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.28445255756378174},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.1849910020828247},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.07574009895324707}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-137440","doi":"https://doi.org/10.1182/blood-2020-137440","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-137440","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2907709010","https://openalex.org/W3097579152","https://openalex.org/W2902758837","https://openalex.org/W2977030866","https://openalex.org/W4405048537","https://openalex.org/W2983802128","https://openalex.org/W2799524374","https://openalex.org/W2737158195","https://openalex.org/W7204683459","https://openalex.org/W4380154581"],"abstract_inverted_index":{"Introduction:":[0],"Acalabrutinib":[1],"is":[2],"an":[3,806],"irreversible":[4],"BTK":[5,34,650],"inhibitor":[6],"(BTKi)":[7],"in":[8,38,52,74,86,110,501,513,545,599,656,668],"the":[9,43,75,156,231,264,298,317,363,397,455,490,564,573,582],"treatment":[10,253,271,393,445],"of":[11,46,92,223,234,267,269,300,334,349,492,591,607,630,637,809,853],"relapsed":[12,67,76],"patients":[13,93,463],"(pts)":[14],"with":[15,71,102,213,247,254,341,559,653],"mantle":[16],"cell":[17],"lymphoma":[18],"(MCL).":[19],"We":[20,62,535],"and":[21,33,49,78,90,120,134,152,179,188,205,221,245,263,292,307,362,375,422,426,436,438,446,452,500,531,549,584,595,612,801,850],"others":[22,199],"have":[23,30,552,626],"previously":[24,555],"reported":[25,554],"that":[26,551],"ibrutinib":[27,39,413,560],"resistant":[28,40],"MCL":[29,53,68,176,410,621,657],"poor":[31,627],"outcomes":[32],"mutations":[35,651],"are":[36,58,97,661],"uncommon":[37],"MCL.":[41,395,669],"However,":[42],"outcomes,":[44],"causes":[45],"discontinuation,":[47],"management":[48,91],"mutational":[50],"landscape":[51],"pts":[54,69,81,112,158,170,212,277,304,309,399,405,428,457,497,622],"who":[55,82,113,159,326,384,400,458,464,476,623],"discontinued":[56,83,160,164,181,385],"acalabrutinib":[57,72,96,116,133,255,270,329,344,366,568,625,654,665],"not":[59,390,442,478,537,648],"described.":[60],"Methods:":[61],"reviewed":[63],"charts":[64],"from":[65,172,587],"all":[66,241,427,487],"treated":[70],"(n=26)":[73],"setting":[77],"identified":[79,598],"21":[80,157],"acalabrutinib,":[84,161,287,302,403,461],"described":[85],"this":[87,643],"analysis.":[88],"Outcomes":[89],"after":[94,138,357],"discontinuing":[95],"reported.":[98],"Whole-exome":[99],"sequencing":[100],"(WES)":[101],"SureSelect":[103],"Human":[104],"All":[105],"Exon":[106],"V6":[107],"was":[108,237,256,272,321,359,368,447],"performed":[109],"9":[111,308],"progressed":[114,401,429,437,459],"on":[115,140,252,286,402,460,567,805],"(10":[117],"tumor":[118],"specimens":[119],"5":[121,288,431],"matched":[122],"germline":[123],"samples);":[124],"among":[125],"these":[126,514,638],"pts,":[127,488],"4":[128],"tumors":[129,515,601],"were":[130,136,289,424,498,508,579,597,614],"collected":[131,137],"before":[132],"6":[135,180,462],"progression":[139,168,374,585],"acalabrutinib.":[141],"One":[142],"patient":[143],"had":[144,216,242,278,305,310,469],"paired":[145],"sample":[146],"at":[147,177,489,602,617],"both":[148,600],"time":[149,299,491],"points":[150],"(baseline":[151],"progression).":[153],"Results:":[154],"Among":[155,396,454],"15":[162,398,456],"(71%)":[163],"due":[165,182,192,200,207,386],"to":[166,174,183,193,201,208,260,387,449,474,556,663],"disease":[167,220],"(2":[169],"transformed":[171],"classic":[173,306],"pleomorphic":[175,314],"progression)":[178],"intolerance":[184,388],"(one":[185],"for":[186,330,345,373,378,394,409],"fatigue":[187],"idiopathic":[189],"encephalopathy,":[190],"one":[191,222,439,588],"unrelated":[194],"severe":[195],"aortic":[196],"stenosis,":[197],"2":[198,206,238],"therapy":[202,468,632],"related":[203],"myelodysplasia":[204],"cardiac":[209,214],"issues).":[210],"Two":[211],"issues":[215],"pre-existing":[217],"coronary":[218],"artery":[219],"them":[224],"developed":[225],"new":[226],"onset":[227],"atrial":[228],"fibrillation.":[229],"Overall,":[230],"median":[232,250,265,318,332,347,364],"number":[233,266,543],"prior":[235,243],"treatments":[236],"(range,":[239,274,323,337,352],"1-3);":[240],"chemo-immunotherapy":[244],"none":[246],"ibrutinib.":[248],"The":[249],"duration":[251,333,348],"8.3":[257,335],"months":[258,336,351,361,370,377],"(1":[259],"50":[261],"months)":[262],"cycles":[268],"8":[273],"1-53).":[275],"Thirteen":[276],"complete":[279],"remission":[280,502],"(CR)":[281],"as":[282],"their":[283],"best":[284],"response":[285],"primary":[290],"refractory":[291,640],"3":[293,419],"achieved":[294,420],"partial":[295],"remission.":[296],"At":[297],"starting":[301],"12":[303],"blastoid":[311],"(n=6)":[312],"or":[313,541,811],"(n=3)":[315],"features,":[316],"Ki-67":[319],"expression":[320],"50%":[322],"10-100).":[324],"Pts":[325],"progressed,":[327],"received":[328,343,406,412,465],"a":[331,346],"1-50)":[338],"while":[339,506],"those":[340,475],"intolerance,":[342],"9.4":[350],"4-31).":[353],"Median":[354],"follow":[355,450,494,504],"up":[356,451,505],"discontinuation":[358],"38":[360],"post":[365],"survival":[367,472,636],"24":[369],"(not":[371],"reached":[372],"7.4":[376],"intolerance;":[379],"p":[380,482],"=0.02,":[381],"Figure-1A-B).":[382],"Patients":[383],"could":[389],"get":[391,479],"subsequent":[392],"14":[404],"systemic":[407],"therapies":[408,415],"[eight":[411],"based":[414],"(4":[416],"non":[417],"responders,":[418],"CR":[421],"1":[423],"PR":[425],"subsequently),":[430],"got":[432],"chemo-immunotherapy,":[433],"bortezomib,":[434],"lenalidomide":[435],"pt":[440],"did":[441,477,536,647],"receive":[443],"any":[444,539],"lost":[448],"died.":[453],"anti-CD19":[466],"CAR-T":[467],"significantly":[470,634],"longer":[471],"compared":[473,580],"CART":[480,631],"therapy;":[481],"=":[483],"0.007,":[484],"Figure-1C.":[485],"For":[486],"last":[493],"up,":[495],"10":[496],"alive":[499],"under":[503],"11":[507],"dead.":[509],"Recurrently":[510],"mutated":[511],"genes":[512],"included":[516],"ATM":[517],"(6/10;":[518],"60%),":[519],"TP53":[520],"(4/10;":[521],"40%),":[522],"KMT2C":[523],"(3/10),":[524],"MYCN":[525],"(2/10),":[526,528,530],"NOTCH1":[527,596],"NOTCH3":[529],"MEF2B":[532],"(2/10)":[533],"(1-D).":[534],"detect":[538],"mutation":[540,565,570,574,606],"copy":[542],"alterations":[544],"BTK,":[546],"PLCG2,":[547],"TRAF2/3":[548],"MYD88":[550],"been":[553],"be":[557],"associated":[558,652],"resistance.":[561],"To":[562],"investigate":[563],"evolution":[566],"treatment,":[569],"profiles,":[571],"particularly":[572],"variant":[575],"allelic":[576],"fractions":[577],"(VAFs),":[578],"between":[581],"baseline":[583],"samples":[586],"patient.":[589],"Mutation":[590],"MYCN,":[592],"MEF2B,":[593],"ATM,":[594],"similar":[603],"VAFs,":[604],"whereas":[605],"CARD11":[608],"(two":[609],"mutations),":[610],"NLRC5":[611],"B2M":[613],"detected":[615],"only":[616],"progression.":[618],"Conclusions:":[619],"Relapsed":[620],"fail":[624],"outcomes.":[628],"Advent":[629],"has":[633],"improved":[635],"heavily":[639],"pts.":[641,658],"In":[642],"small":[644],"cohort,":[645],"we":[646],"observe":[649],"resistance":[655,666],"Further":[659],"studies":[660],"ongoing":[662],"determine":[664],"mechanism":[667],"Disclosures":[670],"Lee:":[671],"Takeda:":[672],"Research":[673,682,686,690,696,701,705,709,713,719,723,727,731,734,738,743,746,750,762,766,770,774,778,781,792,798,816,824,828,832,835,842,846,851,855,860,868,873,882,893,902,905,914,920,924,937,951,954,958,967,975],"Funding;":[674,683,687,691,702,706,710,714,720,724,728,732,739,744,747,751,763,767,771,775,793,799,817,825,829,833,836,843,847,856,861,869,883,894,903,906,915,921,925,938,952,955,959,968,976],"Aptitude":[675],"Health:":[676],"Speakers":[677],"Bureau;":[678],"Bristol-Myers":[679],"Squibb:":[680],"Consultancy,":[681,700,704,708,712,718,722,726,730,791,797,827,831,867,876,888,896,908,919,957,962,974],"Seattle":[684],"Genetics:":[685],"Oncternal":[688],"Therapeutics:":[689,737,741,769,815],"Guidepoint":[692,939],"Blogal:":[693],"Consultancy;":[694,716,785,795,819,838,863,865,871,886,917,941,948,971],"Celgene:":[695,764,796,887],"Funding.":[697,735,779,782,874],"Westin:Astra":[698],"Zeneca:":[699],"Novartis:":[703,748],"Morphosys:":[707],"BMS:":[711],"Amgen:":[715],"Kite:":[717,834],"Genentech:":[721],"Curis:":[725],"Janssen:":[729,772,895],"47:":[733],"Nastoupil:LAM":[736],"TG":[740,814],"Honoraria,":[742,749,761,765,773,777,877,897,909,981],"Merck:":[745],"Gilead/KITE:":[752],"Honoraria;":[753,756,758,930,932,935,946,979],"Gamida":[754],"Cell:":[755],"Bayer:":[757,818],"Genentech,":[759,786],"Inc.:":[760],"Karus":[768],"Pfizer:":[776],"Vega:NCI:":[780],"Flowers:Denovo":[783],"Biopharma:":[784],"Inc./F.":[787],"Hoffmann-La":[788],"Roche":[789],"Ltd:":[790],"Pharmacyclics/Janssen:":[794],"Leukemia":[800],"Lymphoma":[802],"Society:":[803],"Membership":[804],"entity's":[807],"Board":[808],"Directors":[810],"advisory":[812],"committees;":[813],"Eastern":[820],"Cooperative":[821],"Oncology":[822],"Group:":[823,945],"AbbVie:":[826],"Millennium/Takeda:":[830],"Spectrum:":[837],"National":[839],"Cancer":[840,848],"Institute:":[841],"V":[844],"Foundation:":[845,929],"Prevention":[849],"Institute":[852],"Texas:":[854],"Burroughs":[857],"Wellcome":[858],"Fund:":[859],"Karyopharm:":[862],"OptumRx:":[864],"Gilead:":[866],"BeiGene:":[870],"Acerta:":[872],"Wang:AstraZeneca:":[875],"Other:":[878,889,898,910,963,982],"Travel,":[879,890,899,911,964,983],"accommodation,":[880,891,900,912,965,984],"expenses,":[881,892,901,913,966],"Nobel":[884],"Insights:":[885],"VelosBio:":[904],"Pharmacyclics:":[907],"MoreHealth:":[916],"Oncternal:":[918],"Molecular":[922],"Templates:":[923],"Beijing":[926],"Medical":[927,944],"Award":[928],"OncLive:":[931],"Dava":[933],"Oncology:":[934,973,978],"Verastem:":[936],"Global:":[940],"Lu":[942],"Daopei":[943],"InnoCare:":[947],"Acerta":[949],"Pharma:":[950,961],"BioInvent:":[953],"Juno:":[956],"Kite":[960],"Pulse":[969],"Biosciences:":[970],"Loxo":[972],"Targeted":[977],"OMI:":[980],"expenses.":[985]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1}],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2020-11-09T00:00:00"}